ArticleJournal for immunotherapy of cancer2026
Dual-chemokine-armed oncolytic Senecavirus A co-recruits cDC1 and CXCR3
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOncolytic virotherapy represents a promising anticancer strategy by combining direct tumor lysis with in situ immune activation. However, its efficacy remains limited in immune-cold tumors, which are characterized by poor T-cell infiltration and an immunosuppressive microenvironment. Although engineering oncolytic viruses to deliver chemokines has been explored to modulate immune recruitment, most existing approaches activate only a single immune axis. Senecavirus A (SVA), a tumor-selective RNA virus with high genetic stability and flexible transgene capacity, offers an attractive platform for coordinated intratumoral delivery of immune payloads.
methodsWe engineered recombinant SVA vectors to achieve co-expression of CXCL11 and vXCL1 within tumor, aiming to synergistically recruit both T cells and cross-presenting dendritic cells and remodel the tumor immune landscape. In vitro and in vivo assays were conducted to assess viral properties (stability, replication kinetics, gene expression) and cytotoxicity against B16-F10 melanoma cells in different stages, with tumor burden, immune cell infiltration, and mouse survival in C57BL/6 mice analyzed to evaluate the overall therapeutic efficacy.
resultsSignal-peptide deletion significantly improved the genetic stability of transgenes and enhanced intratumoral payload retention, without compromising viral fitness. In murine models, CXCL11-expressing virus monotherapy achieved enhanced tumor control, prolonged survival, and provided preliminary evidence suggestive of protection on tumor rechallenge. Furthermore, the combination of CXCL11 and vXCL1 further augmented dendritic cell activation, promoted CD8
conclusionsOur findings validate the combination of CXCL11- and vXCL1-armed SVA as a potent immunovirotherapy strategy and propose a design principle for multistage, multigene intervention: concurrently targeting leukocyte recruitment, antigen presentation, and effector activation provides complementary mechanisms that synergistically amplify therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.